# Mainz Biomed N.V. (QUCY)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Price:** $1.92 (-5.88%)

> Mainz Biomed N.V. is a molecular genetics diagnostic company specializing in the development of market-ready solutions for the early detection of life-threatening conditions, particularly colorectal and pancreatic cancers. Its flagship product, ColoAlert, is a non-invasive genetic test that outperforms the standard fecal immunochemical test (FIT) in detecting colorectal tumors by analyzing specific genetic markers in stool samples, enabling earlier intervention and better patient outcomes. The company is also advancing proprietary genetic testing methods for pancreatic cancer screening, addressing one of the most challenging areas in oncology diagnostics. Mainz Biomed N.V. focuses on creating simple, affordable, and reliable tools that empower healthcare providers and patients with accessible early detection options, manufactured to high standards including DIN EN ISO 13485 certification. Operating from Mainz, Germany, in a hub for advanced DNA and pharmaceutical research, the company contributes to the biotechnology sector by prioritizing innovative, cost-effective diagnostics that support preventive healthcare strategies worldwide. Founded in 2008, Mainz Biomed N.V. remains dedicated to genetic and genomic testing tailored to individual disease profiles.

Financial data not yet available for this company.

Source: [CompaniesByCap](https://companiesbycap.com/company/QUCY)